Article
Biochemistry & Molecular Biology
Josefine Ruder, Gianna Dinner, Aleksandra Maceski, Ernesto Berenjeno-Correa, Antonia Maria Mueller, Ilijas Jelcic, Jens Kuhle, Roland Martin
Summary: Autologous hematopoietic stem cell transplantation (aHSCT) is an effective treatment for multiple sclerosis (MS), which normalizes pathological processes and enhances beneficial processes. Biomarker analysis of MS patients undergoing aHSCT showed that serum levels of CXCL10, NfL, and GFAP significantly increased one month after transplantation, but returned to normal after one to two years. Levels of GFAP in cerebrospinal fluid (CSF) increased 24 months after aHSCT, indicating sustained astroglia activation. Other CSF markers remained relatively stable.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Peter Alping, Joachim Burman, Jan Lycke, Thomas Frisell, Fredrik Piehl
Summary: This study compares the safety outcomes of different induction therapies for multiple sclerosis patients. It found a higher incidence of thyroid disease in patients treated with alemtuzumab and AHSCT, with a higher incidence of infection in AHSCT-treated patients compared to both alemtuzumab and noninduction therapies. The incidence of nonthyroid autoimmune disease was low for both therapies.
Article
Immunology
Clarissa Heck, Sophie Steiner, Eva M. Kaebisch, Marco Frentsch, Friedrich Wittenbecher, Carmen Scheibenbogen, Leif G. Hanitsch, Axel Nogai, Philipp le Coutre, Lars Bullinger, Igor-Wolfgang Blau, Il-Kang Na
Summary: This study revealed quantitative and functional B cell defects in multiple myeloma patients undergoing auto-HSCT, leading to compromised immune defense. Stimulation with CD40L/IL-21 partially restored TD B cell function, indicating potential extrinsic drivers of the functional B cell defect. Testing CD4+, CD19+, memory B cells, and MZ-like B cells as biomarkers in prospective studies is suggested.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biology
Astrid S. Jorgensen, Viktorija Daugvilaite, Katia De Filippo, Christian Berg, Masa Mavri, Tau Benned-Jensen, Goda Juzenaite, Gertrud Hjorto, Sara Rankin, Jon Vabeno, Mette M. Rosenkilde
Summary: Plerixafor exhibits biased action by reversing the CXCL12 gradient across the bone marrow endothelium and showing superior therapeutic effect in HSC mobilization. In contrast, AMD11070, despite having superior antagonism, does not perform as effectively in HSC mobilization in vivo.
COMMUNICATIONS BIOLOGY
(2021)
Review
Cell & Tissue Engineering
Aiming Pang, Yingying Huo, Biao Shen, Yawei Zheng, Erlie Jiang, Sizhou Feng, Mingzhe Han
Summary: This study highlights the close relationship between clinical outcomes following ASCT and prognostic factors such as patient age, cytogenetic and molecular risk stratification, MRD status, as well as various measurements including pretransplant treatment, stem cell mobilization, collection, conditioning regimens, etc. Consequently, standardization of clinical practice for ASCT is necessary to further enhance patient outcomes.
STEM CELLS TRANSLATIONAL MEDICINE
(2021)
Article
Immunology
Michael Gernert, Hans-Peter Tony, Matthias Froehlich, Eva Christina Schwaneck, Marc Schmalzing
Summary: This study investigated the use of immunosuppressive medication (IS) after autologous hematopoietic stem cell transplantation (aHSCT) in systemic sclerosis (SSc) patients. The results showed that approximately 60% of SSc patients required IS after aHSCT for disease control. Rituximab was found to be an effective treatment option. Long-term data suggested that aHSCT is safe.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Mateusz Nowicki, Agnieszka Wierzbowska, Emilia Stec-Martyna, Dominika Kulczycka-Wojdala, Grzegorz Nowicki, Anna Szmigielska-Kaplon
Summary: The expression levels of SIRT5, SIRT6, and SIRT7 may be associated with the efficacy of hematopoietic stem cell mobilization. Upregulated expressions of SIRT3 and SIRT7 were observed in the complete remission group. These findings contribute to a better understanding of the role of sirtuins during hematopoietic stem cell transplantation.
Article
Multidisciplinary Sciences
Lida Zafeiri, Torbjoern akerfeldt, Andreas Tolf, Kristina Carlson, Alkistis Skalkidou, Joachim Burman
Summary: This study investigated the relationship between AMH levels and age and reproductive potential in MS patients treated with AHSCT. The results showed that although AMH concentration significantly decreased after AHSCT, six patients successfully conceived despite low concentrations, suggesting that high-dose cyclophosphamide treatment may not negatively impact fertility.
Article
Hematology
Alexis Leonard, Akshay Sharma, Naoya Uchida, David Stroncek, Sandhya R. Panch, Kamille West, Eoghan Molloy, Thomas E. Hughes, Sara Hauffe, Tiffani Taylor, Courtney Fitzhugh, Jane S. Hankins, Megan Wilson, Shengdar Q. Tsai, Mitchell J. Weiss, Matthew Hsieh, John F. Tisdale
Summary: Recent studies have shown that plerixafor mobilization and apheresis in patients with sickle cell disease can safely collect sufficient CD34(+) hematopoietic stem cells for clinical gene therapy applications. The quantity of CD34(+) cells mobilized by plerixafor varies among SCD patients for unknown reasons, and factors influencing this yield include age, baseline and pre-apheresis CD34(+) cell counts, and disease severity markers unique to SCD.
Article
Medicine, General & Internal
Francesco Patti, Clara Grazia Chisari, Simona Toscano, Sebastiano Arena, Chiara Finocchiaro, Vincenzo Cimino, Giuseppe Milone
Summary: Multiple sclerosis (MS) is a chronic disease of the central nervous system that can lead to lifelong disability. Despite various treatment options, some patients still face severe symptoms and long-term disability risk. Recent studies have shown that autologous hematopoietic stem cell transplantation (AHSCT) is a highly effective and relatively safe treatment option for highly active MS.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Monika Haubitz, Vittoria S. von Petersdorff, Ingrid Helsen, Claudio Brunold, Elisabeth Oppliger Leibundgut, Gabriela M. Baerlocher
Summary: Autologous hematopoietic stem cell transplantation (autoHSCT) is a highly regulated procedure for the treatment of various diseases. In a retrospective study, 19.6% of adult patients treated with autoHSCT from 2016 to 2019 experienced adverse events (AEs), with 6.0% experiencing adverse reactions (ARs). Factors such as leukapheresis volumes, collected CD34+ cell numbers, transplant volumes, and patient age over 60 significantly correlated with the occurrence and number of AEs. By addressing quality and procedural issues, potentially serious AEs could be reduced by 36.7%, highlighting the need for optimization of the autoHSCT procedure, especially in elderly patients.
Article
Health Care Sciences & Services
Paul Gressenberger, Philipp Jud, Gabor Kovacs, Sonja Kreuzer, Hans-Peter Brezinsek, Katharina Guetl, Viktoria Muster, Ewald Kolesnik, Albrecht Schmidt, Balazs Odler, Gabriel Adelsmayr, Peter Neumeister, Luka Brcic, Sabine Zenz, Kurt Weber, Thomas Gary, Marianne Brodmann, Winfried B. Graninger, Florentine C. Moazedi-Fuerst
Summary: Systemic sclerosis (SSc) is a difficult-to-treat autoimmune disease characterized by vascular damage and organ fibrosis. Autologous hematopoietic stem cell transplantation (AHSCT) may be considered for high-risk SSc patients, but the need for additional immunosuppressive therapies such as rituximab (RTX) post-AHSCT remains unclear. This report highlights the potential efficacy of RTX in SSc patients who do not respond well to AHSCT, with improved clinical symptoms and organ functions observed after RTX treatment.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Immunology
Ane Orrantia, Inigo Terren, Gabirel Astarloa-Pando, Carmen Gonzalez, Alasne Uranga, Juan J. Mateos-Mazon, Juan C. Garcia-Ruiz, Marta Rinon, Mercedes Rey, Silvia Perez-Fernandez, Olatz Zenarruzabeitia, Francisco Borrego
Summary: AutoHSCT in MM patients leads to significant changes in NK cell subsets and phenotype, with patients showing lower frequencies of the mature NKG2A-CD57+ NK cell subset experiencing better clinical outcomes. This suggests that the degree of NK cell maturation post-autoHSCT affects the disease progression and treatment outcomes in MM patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Saskia R. Veldkamp, Marc H. A. Jansen, Joost F. Swart, Caroline A. Lindemans
Summary: This case presents a 9-year-old girl with relapsing polychondritis who underwent autoHSCT initially, experienced a relapse, and ultimately achieved long-term disease remission after successful alloHSCT. The case sheds light on the pathogenesis of relapsing polychondritis with a possible role for CD8(+) T cells, and highlights the potential use of alloHSCT as a treatment option for children with severe autoimmune diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell & Tissue Engineering
Naokazu Nakamura, Tomoyasu Jo, Yasuyuki Arai, Mayumi Matsumoto, Tomomi Sakai, Hiroko Tsunemine, Akifumi Takaori-Kondo, Nobuyoshi Arima
Summary: In a retrospective cohort study of 43 Japanese patients undergoing autologous stem cell transplantation, it was found that the use of plerixafor resulted in a shorter time to neutrophil and platelet engraftment compared to not using plerixafor. Additionally, the incidence of sepsis was significantly lower in the plerixafor group.